SNCE SCIENCE 37 HLDGS INC

Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-Access Innovation

Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-Access Innovation

Seasoned Strategist and Former Chief Commercial Officer Poised to Accelerate Access and Equity in Clinical Research

MORRISVILLE, N.C., Jan. 14, 2025 (GLOBE NEWSWIRE) -- , a leader in enhancing patient access to clinical trials, announces the appointment of Tyler Van Horn as Chief Executive Officer. Formerly the company’s Chief Commercial Officer, Van Horn’s appointment follows his pivotal role in driving operational excellence and shaping the company’s strategic direction to better prioritize client success – initiatives credited with driving growth for the company.

Since joining Science 37 in 2021, Van Horn has been a chief architect in assembling and empowering a team capable of matching or surpassing the testing standards and data quality of traditional clinical trial sites. By emphasizing the well-being and safety of patients through the delivery of convenient, at-home services, Van Horn sees Science 37 solving the most acute patient enrollment and study conduct pain points facing its clinical research clients.

“The future of clinical research lies in enabling therapies to reach their endpoints faster, gaining approval, and ensuring equitable, improved health outcomes for all,” said Van Horn. “As CEO, I am dedicated to supporting sponsors with our world-class research teams and innovative solutions. Our commitment to expanding patient access remains at the heart of everything we do, especially as we strive to reach underserved populations and drive meaningful change in healthcare.”

Van Horn’s elevation to CEO positions Science 37 to seamlessly build upon the learning of past successes. It also redoubles the company’s commitment to growth through purposeful innovation and enhanced solution delivery. By prioritizing the patient and study sponsors, Science 37 is leading the way, ushering in a new era of accessibility, diversity, and patient safety in clinical research.

For more information about Science 37 and its unique approach to clinical research, visit .

About Science 37

Science 37 accelerates clinical research by expanding patient access to trials, leading to faster approvals and better health outcomes. Our Metasite™ and Patient Recruitment solutions enable life sciences companies to reach beyond traditional means of conducting clinical research. To learn more, visit , or email .

To view studies that Science 37 is actively recruiting for, please visit .

Media Inquiries

Science 37



EN
14/01/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SCIENCE 37 HLDGS INC

 PRESS RELEASE

Science 37 Completes Second FDA Inspection as Enrollment Leader in Pha...

Science 37 Completes Second FDA Inspection as Enrollment Leader in Phase 3 Asthma Trial MORRISVILLE, N.C., April 08, 2025 (GLOBE NEWSWIRE) -- , a leader in enhancing patient access to clinical trials, today announced the successful completion of its second FDA inspection, reaffirming the quality of its Direct-to-Patient Site for clinical research. The inspection resulted in a No Action Indicated (NAI) categorization, with no objectionable conditions noted and no Form 483 issued. Led by Science 37's internal Quality Assurance & Compliance team, the inspection focused on the company’s role...

 PRESS RELEASE

Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-...

Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-Access Innovation Seasoned Strategist and Former Chief Commercial Officer Poised to Accelerate Access and Equity in Clinical Research MORRISVILLE, N.C., Jan. 14, 2025 (GLOBE NEWSWIRE) -- , a leader in enhancing patient access to clinical trials, announces the appointment of Tyler Van Horn as Chief Executive Officer. Formerly the company’s Chief Commercial Officer, Van Horn’s appointment follows his pivotal role in driving operational excellence and shaping the company’s strategic direction to better prioritize client ...

 PRESS RELEASE

Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease...

Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease Trial MORRISVILLE, N.C., Nov. 21, 2024 (GLOBE NEWSWIRE) -- , a leader in enhancing patient access to clinical trials, was a key enrolling site for the primary completion of a Phase 3 rare disease trial sponsored by global biopharmaceutical company, . The hepatology study of an investigational medicine for cholestatic pruritus in primary biliary cholangitis (PBC) required 230 global participants, of which Science 37 was able to contribute almost half (17 - 47%) of the U.S. enrollment for the study. Recognizing that t...

 PRESS RELEASE

Science 37 Earns Frost & Sullivan’s 2024 Global Company of the Year Aw...

Science 37 Earns Frost & Sullivan’s 2024 Global Company of the Year Award for Decentralized Clinical Trials Top Honor Recognizes Science 37’s Visionary Innovation, Market-Leading Performance, and Unmatched Customer Care in the Decentralized Clinical Trials Industry MORRISVILLE, N.C., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Today, , a leader in enhancing patient access to clinical trials, announced that it has received Frost & Sullivan’s 2024 Global Company of the Year Award. Recognizing the market participant that exemplifies visionary innovation, market-leading performance, and unmatched cu...

 PRESS RELEASE

Science 37 Unveils New Corporate Headquarters in Research Triangle Par...

Science 37 Unveils New Corporate Headquarters in Research Triangle Park, NC 19,000-square-foot facility reflects the company’s recent growth and continued commitment to the region MORRISVILLE, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- , a leader in enhancing patient access to clinical trials, today announced the grand opening of its new, 19,000-square-foot corporate headquarters in Morrisville, North Carolina, in the heart of Research Triangle Park. The new, state-of-the-art facility, will serve as a hub for all Science 37 operations, enabling cross-functional teams with greater opportun...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch